Who Buys Adalimumab from India — 97 Importers Behind a $1.2M Market

The importers of Adalimumab from India can be categorized into several segments:

1. Distributors: Entities like D. K. M. Pharmaceuticals Pvt. Ltd. in Nepal, which appears multiple times in the top buyer list, function as intermediaries, purchasing Adalimumab in bulk and supplying it to various healthcare providers. Their buying behavior typically involves large, periodic orders to maintain a steady supply chain.

2. Government Procurement Agencies: Organizations such as the United States Pharmacopeial Convention (USA) are involved in setting quality standards and may procure Adalimumab for research or public health initiatives. Their procurement is often characterized by adherence to strict regulatory standards and scheduled tenders.

3. Re-exporters: Companies like Radeep Services in Singapore may import Adalimumab with the intent to re-export to other markets, leveraging Singapore's strategic position as a global trade hub. Their purchasing patterns are influenced by international demand and trade agreements.

4. Hospital Groups and Retail Chains: While not explicitly listed among the top buyers, these entities typically procure Adalimumab directly for patient treatment, focusing on consistent supply to meet patient needs.

5. Contract Manufacturers: These are companies that might import Adalimumab as an active pharmaceutical ingredient (API) for formulation into finished products. Their procurement is usually aligned with production schedules and contractual obligations.

The repeat buyer rate of 48.5% indicates a significant level of recurring demand, suggesting that many importers have established ongoing relationships with Indian exporters to ensure a consistent supply of Adalimumab.

For the top five importing countries, the import regulations for Adalimumab are as follows:

Importers are advised to consult the respective regulatory authorities for the most current information, as regulations and tariffs are subject to change.

The demand for Adalimumab in importing countries is driven by several factors:

1. Disease Prevalence: Adalimumab is primarily used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease. The prevalence of these conditions in countries like Venezuela, Sri Lanka, Nepal, Bangladesh, and the UAE contributes to the consistent demand for this biologic therapy.

2. Government Healthcare Programs: Many of these countries have initiated programs to improve access to essential medicines. For instance, the inclusion of Adalimumab in national formularies and treatment guidelines facilitates its procurement and distribution.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in these regions have led to increased access to biologic therapies, including Adalimumab, as part of comprehensive healthcare services.

4. WHO Essential Medicines List Procurement: While Adalimumab is not currently listed on the WHO Essential Medicines List, its recognition in national essential medicines lists can influence procurement decisions, especially in countries aligning their policies with WHO recommendations.

5. Tender-Based Purchasing: Public sector procurement in these countries often involves competitive tendering processes, which can lead to significant price reductions and increased accessibility of Adalimumab.

The presence of 97 buyers across 53 countries indicates a broad and diverse market for Adalimumab imported from India, reflecting its global demand and the opportunities for Indian exporters to expand their reach.

The importers of Adalimumab from India can be categorized into several segments:

1. Distributors: Entities like D. K. M. Pharmaceuticals Pvt. Ltd. in Nepal, which appears multiple times in the top buyer list, function as intermediaries, purchasing Adalimumab in bulk and supplying it to various healthcare providers. Their buying behavior typically involves large, periodic orders to maintain a steady supply chain.

2. Government Procurement Agencies: Organizations such as the United States Pharmacopeial Convention (USA) are involved in setting quality standards and may procure Adalimumab for research or public health initiatives. Their procurement is often characterized by adherence to strict regulatory standards and scheduled tenders.

3. Re-exporters: Companies like Radeep Services in Singapore may import Adalimumab with the intent to re-export to other markets, leveraging Singapore's strategic position as a global trade hub. Their purchasing patterns are influenced by international demand and trade agreements.

4. Hospital Groups and Retail Chains: While not explicitly listed among the top buyers, these entities typically procure Adalimumab directly for patient treatment, focusing on consistent supply to meet patient needs.

5. Contract Manufacturers: These are companies that might import Adalimumab as an active pharmaceutical ingredient (API) for formulation into finished products. Their procurement is usually aligned with production schedules and contractual obligations.

The repeat buyer rate of 48.5% indicates a significant level of recurring demand, suggesting that many importers have established ongoing relationships with Indian exporters to ensure a consistent supply of Adalimumab.

For the top five importing countries, the import regulations for Adalimumab are as follows:

Importers are advised to consult the respective regulatory authorities for the most current information, as regulations and tariffs are subject to change.

The demand for Adalimumab in importing countries is driven by several factors:

1. Disease Prevalence: Adalimumab is primarily used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease. The prevalence of these conditions in countries like Venezuela, Sri Lanka, Nepal, Bangladesh, and the UAE contributes to the consistent demand for this biologic therapy.

2. Government Healthcare Programs: Many of these countries have initiated programs to improve access to essential medicines. For instance, the inclusion of Adalimumab in national formularies and treatment guidelines facilitates its procurement and distribution.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in these regions have led to increased access to biologic therapies, including Adalimumab, as part of comprehensive healthcare services.

4. WHO Essential Medicines List Procurement: While Adalimumab is not currently listed on the WHO Essential Medicines List, its recognition in national essential medicines lists can influence procurement decisions, especially in countries aligning their policies with WHO recommendations.

5. Tender-Based Purchasing: Public sector procurement in these countries often involves competitive tendering processes, which can lead to significant price reductions and increased accessibility of Adalimumab.

The presence of 97 buyers across 53 countries indicates a broad and diverse market for Adalimumab imported from India, reflecting its global demand and the opportunities for Indian exporters to expand their reach.